This site is intended for health professionals only
Tuesday 22 January 2019
Share |

FDA to consider new Avastin bids

A US Food and Drug Administration (FDA) panel will meet next month to decide on two new uses of Roche's cancer drug Avastin, it has been announced.

The company wants approval for the drug to be used as a first-choice treatment for patients with metastatic HER2-negative breast cancer in combination with the chemotherapy product docetaxel.

Regulators will also consider whether to permit use of Avastin in certain breast cancer patients who have not received chemotherapy.

The drug, Roche's biggest product, is already approved for treating other types of cancer.

Previous research has shown that the drug, when used as a first-choice option, extended the time patients lived without their cancer growing.

The group will meet on July 20.

Copyright Press Association 2010
Food and Drug Administration

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine